A Study of GI-108, an Anti-CD73-IgG4 Fc-IL-2v Bispecific Fusion Protein, as Monotherapy in Patients With Advanced or Metastatic Solid Tumors

StatusRecruiting
PhasePhase 1/2
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Enrollment increased: 76 → 102 participants
    • Eligibility criteria expanded, about 12 words
    • Secondary endpoints: details revised at 1 of 11 entries
    • Study description expanded, about 3 words
  2. Study First Submitted
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
GI Innovation, Inc.
5 trials monitored
See all monitored trials
Lung Cancer
4,822 trials monitored
See 267 trials at risk
Non-Small Cell Lung Cancer (NSCLC)
3,101 trials monitored
See 174 trials at risk
Head & Neck Cancer
2,621 trials monitored
See 150 trials at risk
and 2 more diseases
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and therapeutic activity of GI-108, as a single agent, in patients with advanced or metastatic solid tumors
Trial Details
NCT Number NCT07172802
Lead Sponsor GI Innovation, Inc.
Conditions
(from sponsor)		 Advanced Solid Tumor, Metastatic Solid Tumor, Non-small Cell Lung Cancer (NSCLC), Head and Neck (HNSCC), Pancreatic Cancer, Renal Cell Carcinoma (RCC)
Related terms Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Neoplasm Metastasis, Pancreatic Neoplasms, Squamous Cell Carcinoma of Head and Neck
Enrollment 102 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov